DeepMed Research

Cinacalcet

Generic Name: Cinacalcet

Brand Names: Mimpara, Sensipar, Cinacalcet Mylan, Cinacalcet Accordpharma

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₂F_₃N

CAS Number: 226256-56-0

Unique Ingredient Identifier: UAZ6V7728S

Background: Cinacalcet is a calcimimetic sold by Amgen under the trade name Sensipar® in North America and Australia and as Mimpara® in Europe. It is used to treat hyperparathyroidism due to parathyroid tumours or renal failure.

Indication: For the treatment of secondary hyperparathyroidism in patients with Chronic Kidney Disease who are on hemodialysis or peritoneal dialysis. Also for the treatment of hypercalcemia in patients with parathyroid carcinoma.

Associated Conditions: Hypercalcemia, Secondary Hyperparathyroidism (SHPT)

Clinical Trials

Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet.

Phase 3

Completed

Conditions: Primary Hyperparathyroidism
Parathyroid Adenoma
Parathyroid Hyperplasia

Interventions: Drug: Cinacalcet 30 mg Tablet
Drug: Denosumab Inj 60 mg/ml
Other: Placebo tablets
Other: Saline Injection (Placebo)

First Posted Date: 2017-01-23

Last Posted Date: 2021-05-25

Lead Sponsor: Peter Vestergaard

Target Recruit Count: 46

Registration Number: NCT03027557

Locations: 🇩🇰
Aalborg University Hospital, Aalborg, Denmark

Phase 3 Study of KHK7580

Phase 2

Completed

Conditions: Secondary Hyperparathyroidism

Interventions: Drug: KHK7580
Drug: KRN1493

First Posted Date: 2015-09-15

Last Posted Date: 2017-03-24

Lead Sponsor: Kyowa Kirin Co., Ltd.

Target Recruit Count: 634

Registration Number: NCT02549391

Locations: 🇯🇵
For additional information regarding investigative sites for this trial, contact Kyowa Hakko Kirin, Tokyo, Japan

Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism

Phase 2

Completed

Conditions: Primary Hyperparathyroidism

Interventions: Drug: Placebo
Drug: amiloride
Drug: eplerenone
Drug: Cinacalcet

First Posted Date: 2015-08-17

Last Posted Date: 2023-05-03

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 69

Registration Number: NCT02525796

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Renal Osteodystrophy: An Individual Management Approach

Not Applicable

Completed

Conditions: Kidney Failure, Chronic

Interventions: Drug: Alendronate
Drug: Teriparatide
Drug: Cinacalcet

First Posted Date: 2015-05-12

Last Posted Date: 2023-01-05

Lead Sponsor: Hartmut Malluche, MD

Target Recruit Count: 141

Registration Number: NCT02440581

Locations: 🇺🇸
University of Kentucky, Lexington, Kentucky, United States

Efficacy of Cinacalcet in the Control of Primary Hyperparathyroidism

Phase 4

Completed

Conditions: Hyperparathyroidism, Primary
Osteoporosis

Interventions: Drug: cinacalcet
Drug: Alendronate

First Posted Date: 2015-04-15

Last Posted Date: 2015-04-15

Lead Sponsor: Istituto Auxologico Italiano

Target Recruit Count: 22

Registration Number: NCT02417389

Locations: 🇮🇹
Istituto Auxologico Italiano IRCCS, Milano, Italy

Extension Study of Cinacalcet for Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Patients With Chronic Kidney Disease on Dialysis

Phase 3

Completed

Conditions: Secondary Hyperparathyroidism, Chronic Kidney Disease

Interventions: Drug: Cinacalcet

First Posted Date: 2015-01-19

Last Posted Date: 2020-06-29

Lead Sponsor: Amgen

Target Recruit Count: 28

Registration Number: NCT02341417

Locations: 🇺🇦
Research Site, Kyiv, Ukraine

Primary Hyperparathyroidism: Short-term Calcimimetics Treatment - Relevance for Parathyroid Surgery Decisions?

Not Applicable

Completed

Conditions: Primary Hyperparathyroidism

Interventions: Drug: Cinacalcet
Procedure: parathyroid adenomectomy

First Posted Date: 2014-08-28

Last Posted Date: 2024-08-06

Lead Sponsor: Karolinska University Hospital

Target Recruit Count: 110

Registration Number: NCT02227264

Locations: 🇸🇪
Karolinska University Hospital, Stockholm, Sweden

Phase 2 Study of KHK7580

Phase 2

Completed

Conditions: Secondary Hyperparathyroidism

Interventions: Drug: Placebo
Drug: KHK7580 middle dose
Drug: KRN1493
Drug: KHK7580 low dose
Drug: KHK7580 high dose

First Posted Date: 2014-08-15

Last Posted Date: 2018-07-10

Lead Sponsor: Kyowa Kirin Co., Ltd.

Target Recruit Count: 201

Registration Number: NCT02216656

Locations: 🇯🇵
For additional information regarding investigative sites for this trial, contact Kyowa Hakko Kirin, Tokyo, Japan

Efficacy and Safety of Cinacalcet in Pediatric Patients With Secondary Hyperparathyroidism (SHPT) and Chronic Kidney Disease (CKD) on Dialysis

Phase 3

Terminated

Conditions: Chronic Kidney Disease, Secondary Hyperparathyroidism

Interventions: Drug: Cinacalcet HCl
Dietary Supplement: Standard of Care

First Posted Date: 2014-05-15

Last Posted Date: 2020-06-29

Lead Sponsor: Amgen

Target Recruit Count: 55

Registration Number: NCT02138838

Locations: 🇺🇦
Research Site, Kyiv, Ukraine

A Study to Evaluate the Effect of ASP7991 in Secondary Hyperparathyroidism Patients Undergoing Hemodialysis

Phase 2

Completed

Conditions: Secondary Hyperparathyroidism

Interventions: Drug: Cinacalcet
Drug: ASP7991
Drug: Placebo

First Posted Date: 2014-05-08

Last Posted Date: 2024-11-06

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 62

Registration Number: NCT02133404

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy